menu
    • menu
    [{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"NORWAY","productType":"Vaccine","year":"2020","type":"Licensing Agreement","leadProduct":"TG01","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0.10000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.10000000000000001,"dosageForm":"Injection","sponsorNew":"Targovax \/ IOVaxis Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ IOVaxis Therapeutics"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NORWAY","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"GMCSF","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Valo Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Peptide","year":"2020","type":"Collaboration","leadProduct":"Antigen peptides","moa":"CD8","graph1":"Oncology","graph2":"Undisclosed","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Targovax ","highestDevelopmentStatusID":"1","companyTruncated":"Targovax \/ Targovax "},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Leidos","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Microbially derived peptides","moa":"Checkpoint","graph1":"Oncology","graph2":"Undisclosed","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"1","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"AstraZeneca","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Durvalumab","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intra-peritoneal Infusion","sponsorNew":"Targovax \/ Astrazeneca","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Astrazeneca"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"IOVaxis Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2021","type":"Licensing Agreement","leadProduct":"TG01","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ IOVaxis","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ IOVaxis"},{"orgOrder":0,"company":"Targovax","sponsor":"Theradex","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Theradex","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Theradex"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"Carboplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Oblique Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2020","type":"Collaboration","leadProduct":"Undisclosed","moa":"","graph1":"Oncology","graph2":"Preclinical","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Targovax","highestDevelopmentStatusID":"4","companyTruncated":"Targovax \/ Targovax"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cyclophosphamide","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intratumoral Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Large molecule","year":"2021","type":"Not Applicable","leadProduct":"Cisplatin","moa":"","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Targovax \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Not Applicable"},{"orgOrder":0,"company":"Targovax","sponsor":"Innovation Norway","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Funding","leadProduct":"Gemcitabine","moa":"KRAS","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intramuscular Injection","sponsorNew":"Targovax \/ Innovation Norway","highestDevelopmentStatusID":"7","companyTruncated":"Targovax \/ Innovation Norway"},{"orgOrder":0,"company":"Targovax","sponsor":"Agenus","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2022","type":"Collaboration","leadProduct":"QS-21 Stimulon","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"Targovax","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Targovax \/ Agenus","highestDevelopmentStatusID":"5","companyTruncated":"Targovax \/ Agenus"}]

    Find Clinical Drug Pipeline Developments & Deals by Targovax

    Menu

    Targovax

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib,Stimulon

                            Therapeutic Area : Oncology

                            Study Phase : Undisclosed

                            Sponsor : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Targovax ASA and Agenus Announce Collaboration on Mutant KRAS Cancer Vaccine Adjuvanted With QS-21 STIMULON™

                            Details : Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.

                            Brand Name : TG01

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            March 07, 2022

                            Lead Product(s) : Apricoxib,Stimulon

                            Therapeutic Area : Oncology

                            Highest Development Status : Undisclosed

                            Sponsor : Agenus

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib,Gemcitabine

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Innovation Norway

                            Deal Size : $0.9 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            Innovation Norway Awards NOK 8.2 mn Grant to Targovax for Development of TG Mutant RAS Vaccine

                            Details : With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.

                            Brand Name : TG01

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 12, 2022

                            Lead Product(s) : Apricoxib,Gemcitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Innovation Norway

                            Deal Size : $0.9 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Targovax Granted European Patent for ONCOS-102 in Combination with Chemotherapy

                            Details : The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune sys...

                            Brand Name : ONCOS-102

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            September 24, 2021

                            Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            US FDA Grants Fast Track Status To Targovax ONCOS-102 to Treat Refractory Advanced Melanoma

                            Details : The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses.

                            Brand Name : ONCOS-102

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            June 24, 2021

                            Lead Product(s) : ONCOS-102,Pembrolizumab,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Targovax Releases Presentations of ONCOS-102 Mesothelioma 24-Month Data

                            Details : ONCOS-102, an immune activators used in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma clearly shown tumor responses and survival outcomes.

                            Brand Name : ONCOS-102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 14, 2021

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Targovax’s ONCOS-102 Mesothelioma 24-month Data Shows Class-leading Median Overall Survival

                            Details : The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone.

                            Brand Name : ONCOS-102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 10, 2021

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Theradex

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Continued Survival Benefit in Targovax’s ONCOS-102 Trial in Mesothelioma at the 21-Month Follow-Up

                            Details : The trial is an open label, exploratory phase I/II trial adding ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first and second (and later) line MPM to assess safety, immune activation and clinical efficacy vs SoC only.

                            Brand Name : ONCOS-102

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 23, 2021

                            Lead Product(s) : ONCOS-102,Carboplatin,Cyclophosphamide

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Theradex

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Apricoxib

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : IOVaxis Therapeutics

                            Deal Size : $3.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Targovax Grants IOVaxis 3 Months Extension to the Exclusive License Option for TG Mutant RAS Vaccines in Great...

                            Details : Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore...

                            Brand Name : TG01

                            Molecule Type : Vaccine

                            Upfront Cash : Undisclosed

                            January 06, 2021

                            Lead Product(s) : Apricoxib

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : IOVaxis Therapeutics

                            Deal Size : $3.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Targovax Demonstrates Encouraging Survival Data for ONCOS-102 in Mesothelioma

                            Details : An 18-month analysis shows that median Overall Survival (mOS) will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14.2 months or less in the chemotherapy-only control group.

                            Brand Name : ONCOS-102

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            November 24, 2020

                            Lead Product(s) : ONCOS-102,Cisplatin,Pemetrexed

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed

                            Targovax

                            Norway arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ONCOS-102,Durvalumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Targovax Announces that the Oncos-102 and Durvalumab Trial Successfully Completes Part 1 in Colorectal Cancer

                            Details : The study is a phase I/II trial assessing the combination of intra-peritoneally delivered ONCOS-102 in combination with systemically administered durvalumab, in patients with colorectal or platinum-resistant ovarian cancers that have metastasized to the ...

                            Brand Name : ONCOS-102

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            October 13, 2020

                            Lead Product(s) : ONCOS-102,Durvalumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : AstraZeneca

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth